Testing ravulizumab for kids with IgA nephropathy
Treatments studied
Part of Blood & lymphatic, Heart & circulation, Immune system & allergy, Kidney & urinary, Skin, Women’s health & pregnancy clinical trials.
This study tests a drug called ravulizumab for children aged 2 to under 18 with IgA nephropathy, a kidney condition. It aims to see if the drug can help protect the kidneys and reduce protein in the urine.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Age between 2 and 18 years old.
- Diagnosis of primary IgA nephropathy confirmed by kidney biopsy in the last 3 years.
- Urine protein level (UPCR) of 1.0 g/g or higher from at least 3 morning urine samples.
- Kidney function (eGFR) of 30 mL/min/1.73 m² or higher.
- Must be on a stable, maximum dose of ACE inhibitor or ARB medication for at least 3 months.
- Must have received meningococcal, Hib, and pneumococcal vaccines.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new medicine called telitacicept for children with a kidney condition called IgA vasculitis nephritis. The medicine aims to reduce kidney damage by calming the immune system. Participation may help your child's kidneys stay healthier.
This trial tests a new medicine (FXS6837) for people with IgA nephropathy (a kidney disease that causes protein in the urine and can lead to kidney damage). The goal is to see if it can reduce protein loss and protect kidney function.
This trial tests the drug ravulizumab for people with aHUS (a rare blood and kidney condition). It aims to see if the drug can help improve blood counts and kidney function.
This study tests a new medicine called sibeprenlimab for children and teens with IgA nephropathy, a kidney disease. The medicine may reduce protein in the urine and help protect kidney function.
This study looks at how well patients with aHUS in Poland are doing after treatment with ravulizumab (Ultomiris). It is for people who have already received this drug through the national program and agree to share their health information.
This study tests an investigational medicine (ravulizumab) given through a vein to see if it can prevent delayed graft function—meaning the new kidney takes longer to start working—after a high-risk kidney transplant. It is for adults on dialysis who are getting a kidney from a donor whose heart stopped or who is considered high-risk.
Hear when a new IgAN trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.